StockData
Journey Medical Corp logo

Journey Medical Corp (DERM) stock

DERMNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/3024% below fair value
$4.33−0.06 (-1.37%)

Close on Nov 13, 2026Market cap $122.21MP/E –Yield –

Journey Medical gross margin

Gross margin is gross profit as a percentage of revenue.

Journey Medical's gross margin for the twelve months ending Sep 30, 2026 was 65.9%. For fiscal 2025 it was 66.2%, against 62.8% the year before. The highest annual figure on record is 71.1% in fiscal 2023.

Annual gross margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 202566.2%+3.4
FY2024Dec 31, 202462.8%−8.3
FY2023Dec 31, 202371.1%+12.9
FY2022Dec 31, 202258.2%+9.0
FY2021Dec 31, 202149.2%−18.0
FY2020Dec 31, 202067.2%–

Quarterly gross margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q3 FY2026Sep 30, 202669.0%+1.6
Q2 FY2026Jun 30, 202666.8%−0.3
Q1 FY2026Mar 31, 202661.0%−2.5
Q4 FY2025Dec 31, 202566.2%+0.5
Q3 FY2025Sep 30, 202567.4%−2.1
Q2 FY2025Jun 30, 202567.1%+5.6
Q1 FY2025Mar 31, 202563.5%+9.6
Q4 FY2024Dec 31, 202465.6%−19.6
Q3 FY2024Sep 30, 202469.4%−11.9
Q2 FY2024Jun 30, 202461.4%+9.8
Q1 FY2024Mar 31, 202453.9%−1.3
Q4 FY2023Dec 31, 202385.3%+27.0
Q3 FY2023Sep 30, 202381.4%+16.6
Q4 FY2022Dec 31, 202251.7%+6.0
Q3 FY2022Sep 30, 202255.2%+12.1
Q2 FY2022Jun 30, 202258.3%+7.2
Q1 FY2022Mar 31, 202264.8%+1.2
Q4 FY2021Dec 31, 202145.6%−23.2
Q3 FY2021Sep 30, 202143.1%−21.2
Q2 FY2021Jun 30, 202151.0%–
Q1 FY2021Mar 31, 202163.5%–
Q4 FY2020Dec 31, 202068.8%–
Q3 FY2020Sep 30, 202064.2%–

More Journey Medical figures

See a number that looks wrong?